GMO-GO-PEG-MAN nano-drug delivery material as well as preparation method and detection method thereof
By PEG modification and D-mannose modification on graphene oxide, GMO@GO-PEG-MAN nanodrug delivery material was formed, which solved the problem that gemaxone was difficult to reach the treatment site and achieved targeted delivery of macrophages and controlled release significantly improve the efficacy of the drug.
Patent Information
- Application Number
- CN202411083534.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-08
- Publication Date
- 2024-11-22
AI Technical Summary
Gematone is difficult to reach the site of treatment, the small amount of the drug and the short retention time limit, which limits its effectiveness in treating diseases such as tumors.
By PEG modification of graphene oxide and combined with D-mannose modification, GMO@GO-PEG-MAN nanodrug delivery material was formed, gemmanone was loaded with hydrophobic regions of GO, and through D-mannose and macrophage surfaces were used to form GMO@GO. Mannose receptor binding enables targeted delivery.
It significantly increases the concentration and retention time of gematone in macrophages, extends the drug release time, enhances the efficacy, and achieves controllable drug release under different pH environments, improving the therapeutic effect.
Smart Images

Figure CN118987265A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to a GMO@GO-PEG-MAN nano drug delivery material and a preparation method and a detection method. Background Art
[0002] Macrophages are very important immune cells in the body. They have the functions of identifying foreign bodies, engulfing pathogens, capturing antigens, and secreting a variety of active factors. They play an important role in the body's immune system. In diseases such as tumors and inflammation, they can change their phenotypes due to changes in the tissue microenvironment, release tumor suppressor or tumor-promoting related factors, and play different functions, which are closely related to maintaining the body's metabolic balance and microenvironmental homeostasis. Therefore, precise regulation of the behavior of macrophages will effectively regulate the occurrence and development of diseases.
[0003] Gemmarone (GMO) is a monocyclic sesquiterpenoid compound with multiple pharmacological effects such as anti-inflammatory, antibacterial, anti-tumor, and antiviral, and has certain therapeutic effects on many diseases, such as tumors, cancers, sepsis, etc. However, due to factors such as body metabolism, drug physicochemical properties (poor solubility in water, etc.), and differences in affinity with tissues, the amount of drug that actually reaches the treatment site is small and the retention time is very short, which makes the drug effect insignificant and limits its widespread use. Therefore, it is urgent to develop a suitable drug delivery system to better exert the drug effect.
[0004] In recent decades, targeted drugs and sustained-release drugs based on nanomaterials have become a hot topic in biomedical research. Nanotechnology can improve drug targeting to enhance drug concentration and retention time at the treatment site, thereby enhancing drug efficacy. For example, it can target immune cells such as macrophages. Macrophages, as one of the most important immune regulatory cells in the body, play an important regulatory role in the body's resistance to infection by harmful substances such as viruses and bacteria. Summary of the invention
[0005] Based on the above description, the present invention provides a GMO@GO-PEG-MAN nano drug delivery material and a preparation method and a detection method to solve the problem in the related art that the amount of germacrone reaching the treatment site is small and the retention time is very short.
[0006] The technical solution of the present invention to solve the above technical problems is as follows:
[0007] A GMO@GO-PEG-MAN nano drug delivery material, wherein the drug is germacrone, GO is modified with PEG, MAN terminal targeted molecules are modified, and the hydrophobic region of GO is used to load germacrone;
[0008] Hydroxyl and epoxy groups are distributed on the graphene oxide graphite sheet, and carboxyl and carbonyl groups are introduced at the edge. In 8Arm-PEG-NH2, under the action of EDC, the carboxyl group reacts with the amino group to form an amide bond, which is coupled to the graphene oxide surface.
[0009] D-mannose can bind to the mannose receptors on the surface of macrophages, thereby obtaining a drug delivery material targeted to macrophages.
[0010] The present invention also provides a method for preparing a GMO@GO-PEG-MAN nano drug delivery material:
[0011] A method for preparing a GMO@GO-PEG-MAN nano drug delivery material, including the preparation of a GO-PEG solution, the preparation of a GO-PEG-MAN solution, and the preparation of a GMO@GO-PEG-MAN solution;
[0012] Preparation of the GO-PEG-MAN solution: taking a GO-PEG solution, adding D-mannose, dissolving with water, stirring, dialyzing with pure water, removing excess D-mannose, and obtaining a GO-PEG-MAN solution;
[0013] Preparation of the GMO@GO-PEG-MAN solution: Take the GO-PEG-MAN solution, add germeracone dissolved in methanol, react at 2-8°C for 8-16h, dialyze with pure water to remove the solvent methanol, and obtain the GMO@GO-PEG-MAN solution. Preferably, react at 4°C overnight.
[0014] Based on the above technical solution, the present invention can also be improved as follows.
[0015] Further, the preparation of the GO-PEG solution: take the GO pretreatment solution, add 8Arm-PEG-NH2, adjust the pH to 4.5-6.0, add EDC, ultrasonicate in an ice-water bath, mix overnight at room temperature in the dark, dialyze with pure water, remove excess 8Arm-PEG-NH2, and obtain a GO-PEG solution. The pH is adjusted to 5.45-5.55, and can be 5.5.
[0016] Furthermore, the adding of EDC comprises two steps, firstly, adding 1 / 5 to 1 / 3 of the total mass of EDC, ultrasonicating in an ice-water bath for 8 to 12 minutes, and then adding the remaining EDC, ultrasonicating in an ice-water bath for 18 to 22 minutes.
[0017] Furthermore, the encapsulation efficiency of the prepared GMO@GO-PEG-MAN nano drug delivery material was 50-60%.
[0018] Furthermore, the prepared GMO@GO-PEG-MAN nanodrug delivery material can be stably stored in 10mMPBS or saline solution at 37°C for 7 days.
[0019] Furthermore, the prepared GMO@GO-PEG-MAN nanodrug delivery material released 16.90±0.08% of germacron within 2 hours and 37.38±0.18% of germacron within 72 hours in a simulated blood environment at pH 7.4; and released 21.32±0.34% of germacron within 2 hours and 50.26±0.21% of germacron within 72 hours in a simulated lysosome environment at pH 5.5.
[0020] Furthermore, the method also includes the preparation of C6@GO-PEG-MAN solution, taking GO-PEG-MAN solution, adding coumarin-6 dissolved in methanol, reacting at 4°C overnight, dialyzing with pure water in a dialysis bag, removing the solvent methanol, and obtaining C6@GO-PEG-MAN.
[0021] Furthermore, the method further includes pretreatment of the GO solution: taking the GO solution, adding pure water, 1000g to 14000g: 5 to 30min, centrifugation and washing, adjusting the pH to 6.0 to 8.0, obtaining pretreated GO, adding pure water to the pretreated GO to prepare a 1mg / mL GO pretreatment solution. The pH is preferably 7.0.
[0022] Furthermore, in the preparation of the GO-PEG solution, the instrument used for mixing is a four-dimensional rotating mixer.
[0023] Furthermore, in the preparation of the GO-PEG-MAN solution, the stirring is magnetic stirring overnight.
[0024] The present invention also provides a method for detecting the encapsulation efficiency of a GMO@GO-PEG-MAN nano drug delivery material:
[0025] A method for detecting the encapsulation efficiency of a GMO@GO-PEG-MAN nano drug delivery material, wherein the encapsulation efficiency of the GMO@GO-PEG-MAN nano drug delivery material prepared by the above preparation method is detected by high performance liquid chromatography, and the liquid chromatography conditions are as follows: chromatographic column: WondaSil C18-WR, 4.6×150mm, 5μm; column temperature: 30°C, acetonitrile:pure water in the mobile phase = 80:20, flow rate: 0.8mL / min, detection wavelength: 245nm, injection volume: 20μL.
[0026] The present invention also provides a method for detecting the drug release rate of a GMO@GO-PEG-MAN nano drug delivery material:
[0027] A method for detecting the drug release rate of a GMO@GO-PEG-MAN nano drug delivery material, using high performance liquid chromatography to detect the drug release rate of the GMO@GO-PEG-MAN nano drug delivery material prepared above:
[0028] Take 2% SDS-containing pH = 7.4 PBS buffer dialysis medium and 2% SDS-containing pH = 5.5 PBS buffer dialysis medium in dialysis bags, add GMO@GO-PEG-MAN, seal, protect from light and shake, take samples at 0, 2, 4, 8, 24, 48 and 72 hours, add the same volume of dialysis medium immediately after sampling, and test the concentration of the samples taken by HPLC. The release concentration of germacrone in the dialysis bag at different time periods is calculated, and the cumulative release curve is drawn with time as the horizontal axis and the cumulative release rate as the vertical axis;
[0029] Liquid chromatography conditions: chromatographic column: WondaSil C18-WR, 4.6×150 mm, 5 μm, column temperature: 30°C, mobile phase: acetonitrile: pure water = 80:20, flow rate: 0.8 mL / min, detection wavelength: 245 nm, injection volume: 20 μL.
[0030] Furthermore, the shaking conditions are: a constant temperature shaker at 37° C. and protected from light, shaking at 100 rpm.
[0031] It should be noted that the D-mannose in this article is 4-isothiocyanate phenyl-A-D-mannose; the D-mannose contains an isothiocyanate group that can be covalently coupled to an amino group.
[0032] Compared with the prior art, the technical solution of the present invention has the following beneficial technical effects:
[0033] Functionalized graphene oxide (GO) has become an important research carrier in biology and medicine due to its unique physical and chemical two-dimensional nanomaterial properties and good biocompatibility. At the same time, since mannose receptors are highly present on the surface of macrophages, the present invention constructs D-mannose (MAN)-modified graphene oxide (GO-PEG-MAN) for loading germacron drug to achieve drug targeting of macrophages, thereby obtaining a nanosystem with both drug delivery function and immune regulation function.
[0034] The present invention successfully constructs GMO@GO-PEG-MAN and C6@GO-PEG-MAN (tracing effect) nanomaterials; the GO-PEG-MAN nanomaterial itself has no significant effect on macrophage activity, showing good biocompatibility. The addition of EDC will cause pH changes and GO aggregation. By first adding a small amount of EDC and immediately dispersing it, and then adding more EDC for covalent coupling, the dispersibility of GO and the activity of covalent coupling can be ensured at the same time. Therefore, EDC needs to be added twice. In 8Arm-PEG-NH2, polyethylene glycol can increase solubility and stability.
[0035] The nano drug delivery material of the present invention has different drug release rates under different pH environments, so that GMO@GO-PEG-MAN can be used as a type of intelligent drug delivery material for controllable drug release; GMO@GO-PEG-MAN can enhance the uptake of germacrone by macrophages, and slowly release the drug to delay the decrease of intracellular germacrone concentration, maintain a high intracellular concentration of germacrone level, thereby making the drug effect significant.
[0036] Factors such as body metabolism and tissue affinity limit the amount and duration of germacron in the body. The GMO@GO-PEG-MAN prepared by the present invention can directly target macrophages and gradually release drugs, thereby prolonging the regulation of macrophage function on the body's immune state and cellular microenvironment, which is of great significance for inhibiting the occurrence and development of diseases. The preparation method of the present invention is simple, and it can stably exist in 10mM PBS and physiological saline solution for about 7 days, realizing targeted delivery and directional drug release, enhancing the therapeutic effect while significantly reducing side effects. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] Figure 1 It is the preparation principle diagram of the present invention;
[0038] Figure 2 DLS and Zeta potential diagrams of three replicates of the sample GMO@GO-PEG-MAN detected in the embodiment of the present invention;
[0039] Figure 3 The left figure in the middle is the UV-Vis detection peak graph of GO, GMO, GO-PEG, GO-PEG-MAN, and GMO@GO-PEG-MAN provided in the embodiments of the present invention, and the right figure is the UV-Vis detection peak graph of GO, C6, GO-PEG, GO-PEG-MAN, and C6@GO-PEG-MAN;
[0040] Figure 4 The infrared detection peak diagram of GO, GO-PEG, GO-PEG-MAN, and GMO@GO-PEG-MAN provided in the embodiment of the present invention;
[0041] Figure 5 Appearance morphology diagram of GO, GO-PEG, GO-PEG-MAN, C6@GO-PEG-MAN, and GMO@GO-PEG-MAN detected by transmission electron microscopy provided in the embodiments of the present invention;
[0042] FIG6 is a graph showing the encapsulation efficiency of GMO@GO-PEG-MAN detected by HPLC according to an embodiment of the present invention. Fig. 6A is the standard curve, Figure 6B It is the peak diagram of different concentrations of germacrone solution;
[0043] Figure 7 The drug release rate diagram of GMO@GO-PEG-MAN detected by HPLC within 72 hours at pH = 5.5 and pH = 7.4 provided in the embodiment of the present invention;
[0044] Figure 8 A diagram showing the cytotoxicity of nano drug delivery materials using CCK-8 as provided in an embodiment of the present invention;
[0045] Fig. 9 The embodiment of the present invention provides the use of IF to detect the uptake of nano drug delivery materials by macrophages;
[0046] FIG10 is a diagram showing the changes of germacrone in macrophages detected by HPLC according to an embodiment of the present invention; Fig. 10A The concentration peaks of germacrone and GMO@GO-PEG-MAN in macrophages at 2, 4, 12, and 24 hours of treatment. Fig. 10B It is a bar graph showing the concentration changes of germacron and GMO@GO-PEG-MAN in macrophages after treatment for 2, 4, 12, and 24 hours. DETAILED DESCRIPTION
[0047] In order to facilitate understanding of the present application, the present application will be described more comprehensively below. The present application can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the disclosure of the present application more thorough and comprehensive.
[0048] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this application belongs. The terms used herein in the specification of this application are only for the purpose of describing specific embodiments and are not intended to limit this application.
[0049] The reagents or methods not specifically described in the present invention already exist in the prior art and can be directly purchased from the market or obtained by reference to the prior art.
[0050] A GMO@GO-PEG-MAN nano drug delivery material, wherein the drug is germacrone, GO is modified with PEG, MAN terminal targeted molecules are modified, and the hydrophobic region of GO is used to load germacrone;
[0051] Hydroxyl and epoxy groups are distributed on the graphene oxide graphite sheet, and carboxyl and carbonyl groups are introduced at the edge. In 8Arm-PEG-NH2, under the action of EDC, the carboxyl group reacts with the amino group to form an amide bond, which is coupled to the graphene oxide surface.
[0052] D-mannose can bind to the mannose receptors on the surface of macrophages, thereby obtaining a drug delivery material targeting macrophages. It should be noted that the D-mannose in this article is 4-isothiocyanate phenyl-A-D-mannoside; this D-mannose contains an isothiocyanate group that can be covalently coupled to an amino group.
[0053] A method for preparing a GMO@GO-PEG-MAN nano drug delivery material, such as Figure 1 Shown is a schematic diagram of the preparation principle of the present invention, including the preparation of GO-PEG solution, the preparation of GO-PEG-MAN solution and the preparation of GMO@GO-PEG-MAN solution;
[0054] Pretreatment of GO solution: Take 4 mL of 5 mg / mL GO solution and add 1 mL of pure water to prepare a 4 mg / mL solution; centrifuge and wash at 14000g for 15 min, adjust the pH to 7.0 to obtain pretreated GO, and add pure water to the pretreated GO to prepare a 1 mg / mL GO pretreatment solution.
[0055] Preparation of GO-PEG solution: Take 10mL of the above 1mg / mL GO pretreatment solution, add 100mg8Arm-PEG-NH2, adjust the pH to 5.5 with hydrochloric acid; add 10mg EDC, ultrasonicate in ice water bath for 10min; add 30mg EDC, ultrasonicate in ice water bath for 20min, mix overnight in a four-dimensional rotating mixer at room temperature in the dark. Use 14KD dialysis bag with pure water to dialyze for 12h to remove excess 8Arm-PEG-NH2 to obtain GO-PEG solution.
[0056] Preparation of GO-PEG-MAN solution: Take 4 mL of GO-PEG solution, add 1.2 mg of D-mannose, dissolve in pure water, and stir magnetically overnight. Dialyze with pure water in an 8-14KD dialysis bag for 12 hours to remove excess D-Mannose to obtain GO-PEG-MAN solution.
[0057] Preparation of GMO@GO-PEG-MAN solution: Take 2 mL of GO-PEG-MAN solution, add 1 mL of 1 mg / mL germerocalone (GMO) dissolved in methanol, and react overnight at 4°C. Dialyze with pure water in an 8-14KD dialysis bag for 12 h to remove the solvent methanol to obtain the GMO@GO-PEG-MAN solution.
[0058] Preparation of C6@GO-PEG-MAN solution: Take 2 mL of GO-PEG-MAN solution, add 1 mL of 0.1 mg / mL coumarin-6 (C6) dissolved in methanol, and react overnight at 4°C. Dialyze with pure water in an 8-14KD dialysis bag for 12 h to remove the solvent methanol to obtain C6@GO-PEG-MAN solution.
[0059] Furthermore, the encapsulation efficiency of the prepared GMO@GO-PEG-MAN nano drug delivery material was 50-60%.
[0060] Furthermore, the prepared GMO@GO-PEG-MAN nanodrug delivery material can be stably stored in 10mMPBS or saline solution at 37°C for 7 days.
[0061] Furthermore, the prepared GMO@GO-PEG-MAN nanodrug delivery material released 16.90±0.08% of germacron within 2 hours and 37.38±0.18% of germacron within 72 hours in a simulated blood environment at pH 7.4; and released 21.32±0.34% of germacron within 2 hours and 50.26±0.21% of germacron within 72 hours in a simulated lysosome environment at pH 5.5.
[0062] The present invention also provides a method for detecting the encapsulation efficiency of a GMO@GO-PEG-MAN nano drug delivery material:
[0063] A method for detecting the encapsulation efficiency of a GMO@GO-PEG-MAN nano drug delivery material, wherein the encapsulation efficiency of the GMO@GO-PEG-MAN nano drug delivery material prepared by the above preparation method is detected by high performance liquid chromatography, and the liquid chromatography conditions are as follows: chromatographic column: WondaSil C18-WR, 4.6×150mm, 5μm; column temperature: 30°C, acetonitrile:pure water in the mobile phase = 80:20, flow rate: 0.8mL / min, detection wavelength: 245nm, injection volume: 20μL.
[0064] The present invention also provides a method for detecting the drug release rate of a GMO@GO-PEG-MAN nano drug delivery material:
[0065] A method for detecting the drug release rate of a GMO@GO-PEG-MAN nano drug delivery material, using high performance liquid chromatography to detect the drug release rate of the GMO@GO-PEG-MAN nano drug delivery material prepared above:
[0066] Take 2% SDS-containing pH = 7.4 PBS buffer dialysis medium and 2% SDS-containing pH = 5.5 PBS buffer dialysis medium in dialysis bags, add GMO@GO-PEG-MAN, seal, protect from light and shake, take samples at 0, 2, 4, 8, 24, 48 and 72 hours, add the same volume of dialysis medium immediately after sampling, and test the concentration of the samples taken by HPLC. The release concentration of germacrone in the dialysis bag at different time periods is calculated, and the cumulative release curve is drawn with time as the horizontal axis and the cumulative release rate as the vertical axis;
[0067] Liquid chromatography conditions: chromatographic column: WondaSil C18-WR, 4.6×150 mm, 5 μm, column temperature: 30°C, mobile phase: acetonitrile: pure water = 80:20, flow rate: 0.8 mL / min, detection wavelength: 245 nm, injection volume: 20 μL.
[0068] Furthermore, the shaking conditions are: a constant temperature shaker at 37°C and protected from light, shaking at 100 rpm. Example 1 Preparation method of GMO@GO-PEG-MAN and C6@GO-PEG-MAN
[0069] The present invention performs PEG modification on GO, performs MAN terminal targeted molecule modification, utilizes the hydrophobic region of GO to load germacrone, and performs relevant characterization and cell experiments (detailed steps are as follows).
[0070] Graphene oxide has good biocompatibility and drug delivery function, and has a large specific surface area. Hydroxyl and epoxy groups are distributed on the graphene sheet, and carboxyl and carbonyl groups are introduced on the edge. It has a large number of surface functional groups and can be used for surface modification. Drugs can be combined through π-π stacking, hydrogen bonding, hydrophobic interaction and electrostatic interaction.
[0071] In 8Arm-PEG-NH2 (a PEG derivative with eight arms and an amino terminal), the amino group reacts with the carboxyl group under the action of carbodiimide compounds (EDC) to form an amide bond, coupling the material to the surface of the nanomaterial. Polyethylene glycol can increase solubility and stability.
[0072] Mannose receptor is a C-type lectin mainly present on the surface of macrophages and can be used as a type of specific membrane receptor for designing macrophage-targeted drug delivery materials.
[0073] S1, take 4 mL of 5 mg / mL GO solution, add 1 mL of pure water to prepare 4 mg / mL solution, centrifuge and wash at 14000g for 15 min, adjust the pH to 7.0, and obtain pretreated GO.
[0074] S2, the above pretreated GO was prepared into a 1 mg / mL solution, 10 mL was taken, 100 mg 8Arm-PEG-NH2 was added, and the pH was adjusted to 5.5 with hydrochloric acid to obtain a primary GO solution.
[0075] S3, take the primary GO solution, add 10 mg EDC, and ultrasonicate in an ice-water bath for 10 min.
[0076] S4, add 30 mg EDC, ultrasonicate in an ice-water bath for 20 min, mix overnight in a four-dimensional rotating mixer at room temperature in the dark; dialyze with pure water in a 14KD dialysis bag for 12 h to remove excess 8Arm-PEG-NH2 to obtain GO-PEG solution.
[0077] S5, take 4 mL GO-PEG solution, add 1.2 mg D-mannose, dissolve in pure water, and stir magnetically overnight; dialyze with pure water in an 8-14KD dialysis bag for 12 hours to remove excess D-Mannose to obtain GO-PEG-MAN solution.
[0078] S6, take 2mL GO-PEG-MAN solution, add 1mL 1mg / mL germercaptoethanol (GMO), and react at 4℃ overnight; dialyze with pure water in 8-14KD dialysis bag for 12h to remove the solvent methanol to obtain GMO@GO-PEG-MAN solution.
[0079] S7, take 2 mL of GO-PEG-MAN solution, add 1 mL of 0.1 mg / mL coumarin-6 (C6) dissolved in methanol, and react at 4°C overnight; dialyze with pure water in an 8-14KD dialysis bag for 12 h to remove the solvent methanol to obtain C6@GO-PEG-MAN.
[0080] Test 1DLS and Zeta Potential Detection
[0081] The GO, GO-PEG, GO-PEG-MAN, GMO@GO-PEG-MAN, and C6@GO-PEG-MAN solutions were subjected to DLS and Zeta detection using a nanoparticle size analyzer (DLS, Malvem, UK). Figure 2 shown.
[0082] Test results: After the samples GO, GO-PEG, GO-PEG-MAN, GMO@GO-PEG-MAN and C6@GO-PEG-MAN were successfully prepared as required, they were tested using DLS and Zeta potential. The results of DLS and Zeta potential showed that with the gradual modification of the compounds, the hydrated particle size of the particles increased, the potential was generally negatively charged, and the absolute value decreased, which was consistent with the effect of compound modification.
[0083] Table 1 DLS and Zeta potential test results
[0084]
[0085] Test 2UV-Vis
[0086] The GO, GO-PEG, GO-PEG-MAN, C6@GO-PEG-MAN, and GMO@GO-PEG-MAN solutions were diluted with pure water and tested using an ultraviolet-visible spectrophotometer (UV1780, manufacturer: Shimadzu, Japan).
[0087] Test results: UV-visible spectrophotometer was used to detect GO, GMO, GO-PEG, GO-PEG-MAN, GMO@GO-PEG-MAN, C6, and C6@GO-PEG-MAN. Figure 3 As shown in the figure, it was found that germerone has obvious absorption in the wavelength range of 200-280nm. Since GO itself has strong absorption interference in this range, the absorption peak of GMO@GO-PEG-MAN has no obvious change. Coumarin-6 has absorption peaks at 415nm and 473nm, so the absorption peak of C6@GO-PEG-MAN group has obvious changes in the range of 400-500nm.
[0088] Test 3 Infrared detection of GO, GO-PEG, GO-PEG-MAN, GMO@GO-PEG-MAN
[0089] GO, GO-PEG, GO-PEG-MAN, and GMO@GO-PEG-MAN were detected using an infrared detector. Figure 4 As shown in the figure, the results show that the peak shapes and positions of the three groups of products are significantly different from those of GO in infrared spectrum detection, among which 2870cm -1 A new peak appears at 1350cm -1 A new peak appears at 1386cm -1 The newly added peak is caused by the rich -CH3 on GMO. It shows that germerone is successfully loaded onto the nanomaterial to obtain GMO@GO-PEG-MAN material.
[0090] Test 4 Transmission electron microscopy observation
[0091] GO, GO-PEG, GO-PEG-MAN, C6@GO-PEG-MAN, and GMO@GO-PEG-MAN were dropped onto a copper grid and dried before being imaged using a transmission electron microscope (pHilips, Holland). GO, GO-PEG, GO-PEG-MAN, C6@GO-PEG-MAN, and GMO@GO-PEG-MAN were detected using a transmission electron microscope. Figure 5 shown.
[0092] The results showed that the GMO@GO-PEG-MAN sample showed a flake structure with a size of about 70-200 nm in the electron microscopy image. Compared with the morphology of GO, the morphology did not change significantly after modification and drug loading. Test 5 used high performance liquid chromatography (HPLC) to detect the encapsulation efficiency
[0093] Liquid chromatography conditions: chromatographic column: WondaSil C18-WR (4.6×150 mm, 5 μm), column temperature: 30°C, mobile phase: acetonitrile: pure water = 80:20, flow rate: 0.8 mL / min, detection wavelength: 245 nm, injection volume: 20 μL.
[0094] Accurately weigh the germacrone reference substance, dissolve it in methanol and dilute it into a series of standard solutions with concentrations of 100, 50, 25, 12.5, and 6.25 μg / mL, respectively. Determine it under the above-mentioned HPLC conditions, and draw a standard curve with solution concentration (μg / mL) as the abscissa and peak area as the ordinate, as shown in the figure. Fig. 6A As shown, the peak diagrams of different concentrations of germacron solution are as follows Figure 6B As shown. Ultrafiltration test encapsulation efficiency: Take the sample solution after reaction, ultrafilter it with 100KD ultrafiltration tube, collect 2mL of filtrate, wash and resuspend the retained sample with pure water. Dilute the filtrate 10 times with methanol and test it. Test it three times in parallel according to the above chromatographic conditions. Calculate the concentration of the filtrate of the sample after reaction according to the standard curve, and calculate the encapsulation efficiency. The encapsulation efficiency refers to the percentage of the encapsulated substance (such as germacron) on the nanoparticles to the total amount of drug added.
[0095] The formula for calculating the encapsulation rate is: Encapsulation rate = (dosage - amount of drug in the filtrate) / dosage * 100%. In this test, the encapsulation rate = (1 mL * 1 mg / mL * 1000 - 22.8050 μg / mL * 2 mL * 10) / (1 mL * 1 mg / mL * 1000) * 100% = 54.39%.
[0096] The results showed that the encapsulation efficiency of the drug delivery material was 54.39%.
[0097] Table 2 HPLC detection of GMO@GO-PEG-MAN encapsulation efficiency
[0098]
[0099] Test the stability of 6 nano drug delivery materials in PBS solution, saline solution, and DMEM culture medium
[0100] The stability of GO-PEG-MAN and GMO@GO-PEG-MAN in PBS solution, saline solution and DMEM culture medium was evaluated by DLS and Zeta potential using a nanoparticle size and Zeta potential analyzer. The results showed that GO-PEG-MAN and GMO@GO-PEG-MAN were stable for 7 days in 10mM PBS and saline solution at 37°C, and aggregation occurred on the 3rd day in DMEM culture medium solution (both Z-averge and PDI changed significantly); GMO@GO-PEG-MAN was stable for 7 days in 10mM PBS and saline solution at 37°C, and aggregation occurred on the 5th day in DMEM culture medium solution.
[0101] Table 3 DLS and Zeta potential were used to evaluate the stability of GO-PEG-MAN and GMO@GO-PEG-MAN in PBS solution, saline, and DMEM culture medium, n=3 (i.e., 3 replicates for each sample).
[0102]
[0103]
[0104] Test 7: Drug release rate detection
[0105] HPLC was used to detect the drug release of GMO@GO-PEG-MAN: 9 mL of 2% SDS-containing pH = 7.4 PBS buffer dialysis medium and 9 mL of 2% SDS-containing pH = 5.5 PBS buffer dialysis medium were placed in dialysis bags (MW: 8-14k), and 1 mL of GMO@GO-PEG-MAN was added to each bag. The bags were sealed and placed in a constant temperature shaker at 37°C and away from light, with an oscillation of 100 rpm. 2 mL of samples were taken at 0, 2, 4, 8, 24, 48 and 72 h, and the same volume of dialysis medium was immediately added after sampling. The concentration of the samples taken out was tested by HPLC, and the release concentration of germacrone in the dialysis bag at different time periods was calculated. The cumulative release curve was drawn with time as the horizontal axis and the cumulative release rate as the vertical axis, as shown in the figure. Figure 7 shown.
[0106] Liquid chromatography conditions: chromatographic column: WondaSil C18-WR (4.6×150 mm, 5 μm), column temperature: 30°C, mobile phase: acetonitrile: pure water = 80:20, flow rate: 0.8 mL / min, detection wavelength: 245 nm, injection volume: 20 μL.
[0107] The formula for calculating the drug release rate is:
[0108] The formula for the drug release rate at the nth point is (C n *10mL+∑(C1+C2+…C n-1 )*2mL) / m (total drug mass of released sample);
[0109] C = concentration, unit: μg / mL; m = total drug mass of released sample, unit: μg.
[0110] m = sample concentration * 1mL = 543.9μg / mL * 1mL = 543.9μg
[0111] The results showed that at pH 7.4 (simulating blood environment), GMO@GO-PEG-MAN released 16.90±0.08% of germazine within 2 hours and 37.38±0.18% of germazine within 72 hours; at pH 5.5 (simulating lysosomal environment), GMO@GO-PEG-MAN released 21.32±0.34% of germazine within 2 hours and 50.26±0.21% of germazine within 72 hours, indicating that the acidic environment promotes the release of germazine in GMO@GO-PEG-MAN.
[0112] Test 8 Cytotoxicity Assay
[0113] The cytotoxicity of GO, GO-PEG, GMO, GMO@GO-PEG and GMO@GO-PEG-MAN was detected by CCK-8 method. First, cells were seeded in 96-well culture plates at a density of 5000 cells / well. After 12 h of culture, the cells were exposed to 200 μL of fresh culture medium containing GO, GO-PEG, GMO, GMO@GP-PEG and GMO@GO-PEG-MAN for 72 h. Afterwards, the culture medium was replaced with 100 μL of fresh culture medium, and then 10 μL of CCK-8 detection reagent was added. After 4 h of culture, the optical density (OD) at 450 nm was measured using a microplate reader.
[0114] CCK-8 was used to detect the cytotoxicity of nano-drug delivery materials on macrophages. Figure 8,The results showed that compared with the control group, there was no significant difference in ,the cell activity of GO, GO-PEG, GMO, GMO@GO-PEG, and GMO@GO-PEG-MAN groups, ,indicating that GMO@GO-PEG-MAN showed good biocompatibility and ,was non-toxic to macrophages in vitro.
[0115] Test 9 Targeted uptake experiment
[0116] The uptake of nano drug delivery materials by macrophages was detected by IF immunofluorescence technique using an inverted fluorescence microscope: The uptake of NPs (nanoparticles) in cells was evaluated by fluorescence. THP-1 cells were stimulated with 100 nm PMA for 24 h, followed by C6@GO-PEG and C6@GO-PEG-MAN for 1 h, 2 h, and 4 h, respectively. Subsequently, the cells were washed three times with PBS, fixed with 4% paraformaldehyde for 20 min, and the nuclei were stained with DAPI solution for 15 min, and the cells were exposed to a fluorescence microscope.
[0117] IF immunofluorescence technique was used to detect the uptake of nano-drug delivery materials by macrophages. Targeted uptake fluorescence experiments were performed. Fig. 9 ,The results showed that the fluorescence of the same material increased with time, and the fluorescence ,intensity of C6@GO-PEG-MAN was greater than that of C6@GO-PEG at the same ,treatment time, indicating that MAN can effectively target macrophages.
[0118] Test 10 HPLC detection of germacrone concentration in macrophages
[0119] THP-1 cells were cultured at 2 × 10 6 Cells / well were seeded into 6-well plates and stimulated with 100 nM PMA for 48 h, then treated with 5 μg / mL germer or 5 μg / mL GMO@GO-PEG-MAN for 2, 4, 12, and 24 h; washed twice with PBS, then digested with 200 uL trypsin for 2 min, resuspended in 500 uL complete medium, counted, centrifuged at 1500 rpm for 3 min, discarded the supernatant, washed twice with 500 uL PBS, aspirated the supernatant, added 100 uL protein lysis buffer (RIPA) (Thermo Fisher) for 30 min, frozen at -20 °C, and then detected the GMO concentration by HPLC (Agilent Technologies, Santa Clara, CA), as shown in Figure 2. Fig. 10A The concentration peaks of germacrone and GMO@GO-PEG-MAN in macrophages at 2, 4, 12, and 24 hours. Fig. 10B It is a bar graph showing the concentration changes of germacron and GMO@GO-PEG-MAN in macrophages after treatment for 2, 4, 12, and 24 hours.
[0120] The results showed that after the drug action, the intracellular content of germacruconate decreased with time. GMO@GO-PEG-MAN can enhance the cell's uptake of germacruconate and delay the decline of intracellular germacruconate concentration.
[0121] Reagents involved in the present invention
[0122] Experimental reagents:
[0123]
[0124] Experimental Instruments
[0125]
[0126] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. A GMO@GO-PEG-MAN nano drug delivery material, characterized in that: The drug is germacruin, GO is modified with PEG, D-mannose terminal targeted molecule is modified, and the hydrophobic region of GO is used to load germacruin; Hydroxyl and epoxy groups are distributed on the graphene oxide graphite sheet, and carboxyl and carbonyl groups are introduced at the edge. In 8Arm-PEG-NH2, under the action of EDC, the carboxyl group reacts with the amino group to form an amide bond, which is coupled to the graphene oxide surface. D-mannose can bind to the mannose receptors on the surface of macrophages, thereby obtaining a drug delivery material targeted to macrophages.
2. A method for preparing a GMO@GO-PEG-MAN nano drug delivery material, characterized in that: Including the preparation of GO-PEG solution, the preparation of GO-PEG-MAN solution and the preparation of GMO@GO-PEG-MAN solution; Preparation of the GO-PEG-MAN solution: taking a GO-PEG solution, adding D-mannose, dissolving with water, stirring, dialyzing with pure water, removing excess D-mannose, and obtaining a GO-PEG-MAN solution; Preparation of the GMO@GO-PEG-MAN solution: Take a GO-PEG-MAN solution, add germercaptoethanol dissolved in methanol, react at 2-8° C. for 8-16 hours, dialyze with pure water to remove the solvent methanol, and obtain a GMO@GO-PEG-MAN solution.
3. The method for preparing a GMO@GO-PEG-MAN nano drug delivery material according to claim 2, characterized in that: Preparation of the GO-PEG solution: Take a GO pretreatment solution, add 8Arm-PEG-NH2, adjust the pH to 4.5-6.0, add EDC, sonicate in an ice-water bath, mix overnight at room temperature in the dark, dialyze with pure water to remove excess 8Arm-PEG-NH2, and obtain a GO-PEG solution.
4. The method for preparing a GMO@GO-PEG-MAN nano drug delivery material according to claim 3, characterized in that: The adding of EDC comprises two steps: firstly, adding 1 / 5 to 1 / 3 of the total mass of EDC, ultrasonicating in an ice-water bath for 8 to 12 minutes, and then adding the remaining EDC, ultrasonicating in an ice-water bath for 18 to 22 minutes.
5. The method for preparing a GMO@GO-PEG-MAN nano drug delivery material according to claim 2, characterized in that: The encapsulation efficiency of the prepared GMO@GO-PEG-MAN nano drug delivery material is 50-60%.
6. The method for preparing a GMO@GO-PEG-MAN nano drug delivery material according to any one of claims 2 to 5, characterized in that: The prepared GMO@GO-PEG-MAN nanodrug delivery material can be stably stored in 10mM PBS or saline solution at 37°C for 7 days.
7. The method for preparing a GMO@GO-PEG-MAN nano drug delivery material according to any one of claims 2 to 5, characterized in that: The prepared GMO@GO-PEG-MAN nanodrug delivery material released 16.90±0.08% of germacrone within 2 hours and 37.38±0.18% of germacrone within 72 hours in a simulated blood environment at pH 7.4; in a simulated lysosome environment at pH 5.5, 21.32±0.34% of germacrone was released within 2 hours and 50.26±0.21% of germacrone was released within 72 hours.
8. A method for detecting the encapsulation efficiency of a GMO@GO-PEG-MAN nano drug delivery material, characterized in that: The encapsulation efficiency of a GMO@GO-PEG-MAN nano drug delivery material prepared by the preparation method according to any one of claims 2 to 5 was detected by high performance liquid chromatography, and the liquid chromatography conditions were as follows: chromatographic column: WondaSil C18-WR, 4.6×150 mm, 5 μm; Column temperature: 30°C, mobile phase: acetonitrile: pure water = 80:20, flow rate: 0.8 mL / min, detection wavelength: 245 nm, injection volume: 20 μL.
9. A method for detecting the drug release rate of a GMO@GO-PEG-MAN nano drug delivery material, characterized in that: The drug release rate of the GMO@GO-PEG-MAN nano drug delivery material of claim 1 was detected by high performance liquid chromatography: Take 2% SDS-containing PBS buffer dialysis medium at pH = 7.4 and 2% SDS-containing PBS buffer dialysis medium at pH = 5.5 in dialysis bags, add GMO@GO-PEG-MAN, seal, protect from light and shake, take samples at 0, 2, 4, 8, 24, 48 and 72 hours, and immediately add the same volume of dialysis medium after sampling. The concentration of the taken samples is detected by HPLC, and the release concentration of germacrone in the dialysis bag at different time periods is calculated, and the cumulative release curve is drawn with time as the horizontal axis and the cumulative release rate as the vertical axis; Liquid chromatography conditions: chromatographic column: WondaSil C18-WR, 4.6×150 mm, 5 μm, column temperature: 30°C, mobile phase: acetonitrile: pure water = 80:20, flow rate: 0.8 mL / min, detection wavelength: 245 nm, injection volume: 20 μL.
10. The method for detecting drug release rate of a GMO@GO-PEG-MAN nano drug delivery material according to claim 9, characterized in that: The shaking conditions were: a constant temperature shaker at 37°C and protected from light, shaking at 100 rpm.
